Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Introduction

Some drugs cause tongue disorders as adverse effects. Most of the drug-induced tongue disorders are benign and will resolve after drug discontinuation. However, the changes in the color or appearance of the tongue may frighten patients and decrease compliance with drug therapy.

Objective

To review the literature to find all reports of drug-induced tongue disorders, their presentation, management, and outcome of patients.

Methods

The search was conducted in Google Scholar and PubMed using key words “ageusia,” “burning tongue,” “coated tongue,” “drug-induced taste disturbances,” “dysgeusia,” “glossitis,” “glossodynia," “hairy tongue,” “hypogeusia,” “stomatodynia,” “stomatopyrosis,” “swollen tongue” “tongue discoloration,” “tongue irritation,” “tongue numbness, “tongue oedema,” and “tongue ulcer. All reports that were published from 1980 to 2022 in the English language were included in the study. Reports that were not in English language but had English abstracts with adequate data for extraction were also included.

Results

A total of 208 case reports and case series were included. The most reported drug classes were antineoplastic and immunomodulating agents and anti-infectives for systemic use, and the most common tongue disorders were tongue discoloration and black hairy tongue. Having good oral hygiene and discontinuing the offending drug could manage and resolve the problem.

Conclusion

Drug-induced tongue disorders are not rare adverse drug reactions. They are benign in most cases, and withholding offending agents results in significant improvement or complete resolution of tongue lesions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863299971240513061630
2025-05-01
2025-10-03

  • From This Site

    /content/journals/cds/10.2174/0115748863299971240513061630
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MangoldA.R. TorgersonR.R. RogersR.S.III Diseases of the tongue.Clin. Dermatol.201634445846910.1016/j.clindermatol.2016.02.018 27343960
     [Google Scholar]
  2. AzizY. RademacherW.M.H. HielemaA. Oral adverse effects: Drug‐induced tongue disorders.Oral Dis.20212761528154110.1111/odi.13680 33052611
     [Google Scholar]
  3. GurvitsG.E. TanA. Black hairy tongue syndrome.World J. Gastroenterol.20142031108451085010.3748/wjg.v20.i31.10845 25152586
     [Google Scholar]
  4. GondakR.O. da Silva-JorgeR. JorgeJ. LopesM.A. VargasP.A. Oral pigmented lesions: Clinicopathologic features and review of the literature.Med. Oral Patol. Oral Cir. Bucal2012176e919e92410.4317/medoral.17679 22549672
     [Google Scholar]
  5. SchlagerE. St ClaireC. AshackK. KhachemouneA. Black hairy tongue: Predisposing factors, diagnosis, and treatment.Am. J. Clin. Dermatol.201718456356910.1007/s40257‑017‑0268‑y 28247090
     [Google Scholar]
  6. FellerL. FourieJ. BouckaertM. KhammissaR.A.G. BallyramR. LemmerJ. Burning mouth syndrome: Aetiopathogenesis and principles of management.Pain Res. Manag.201720171610.1155/2017/1926269 29180911
     [Google Scholar]
  7. KleinB. ThoppayJ.R. De RossiS.S. CiarroccaK. Burning mouth syndrome.Dermatol. Clin.202038447748310.1016/j.det.2020.05.008 32892856
     [Google Scholar]
  8. BalasubramaniamR. KlasserG.D. DelcanhoR. Separating oral burning from burning mouth syndrome: Unravelling a diagnostic enigma.Aust. Dent. J.200954429329910.1111/j.1834‑7819.2009.01153.x 20415926
     [Google Scholar]
  9. SoaresM.S. Chimenos-KüstnerE. Subirá-PifarrèC. Rodríguez de Rivera-CampilloM.E. López-LópezJ. Association of burning mouth syndrome with xerostomia and medicines.Med. Oral Patol. Oral Cir. Bucal2005104301308 16056186
     [Google Scholar]
  10. SinghaK.B. KonarS. MondalM.K. DasJ. Scanning electron microscopic study of the human fungiform papillae.J. Anat. Soc. India201059215415710.1016/S0003‑2778(10)80016‑4
     [Google Scholar]
  11. Mantilla GómezS. DanserM.M. SiposP.M. RowshaniB. Van Der VeldenU. Van Der WeijdenG.A. Tongue coating and salivary bacterial counts in healthy/gingivitis subjects and periodontitis patients.J. Clin. Periodontol.2001281097097810.1034/j.1600‑051x.2001.028010970.x 11686816
     [Google Scholar]
  12. SeerangaiyanK. JüchF. WinkelE.G. Tongue coating: Its characteristics and role in intra-oral halitosis and general health—a review.J. Breath Res.201812303400110.1088/1752‑7163/aaa3a1 29269592
     [Google Scholar]
  13. WalkerH.K. HallW.D. HurstJ.W. Clinical methods: The history, physical, and laboratory examinations.United KingdomButterworth-Heinemann19901118
     [Google Scholar]
  14. YaegakiK. SanadaK. Biochemical and clinical factors influencing oral malodor in periodontal patients.J. Periodontol.199263978378910.1902/jop.1992.63.9.783 1474480
     [Google Scholar]
  15. MardiaI.S. Relationship between glycemic control and coated tongue in type 2 diabetes mellitus patients with xerostomia.Pesqui. Bras. Odontopediatria Clin. Integr.2020202019
     [Google Scholar]
  16. WalukowW.G. Gambaran Xerostomia pada Penderita Diabetes Melitus Tipe 2 di Poliklinik Endokrin RSUP.e-GIGI201312322410.35790/eg.1.2.2013.3224
     [Google Scholar]
  17. JainkittivongA. LanglaisR.P. Geographic tongue: Clinical characteristics of 188 cases.J. Contemp. Dent. Pract.20056112313510.5005/jcdp‑6‑1‑123 15719084
     [Google Scholar]
  18. AssimakopoulosD. PatrikakosG. FotikaC. ElisafM. Benign migratory glossitis or geographic tongue: An enigmatic oral lesion.Am. J. Med.2002113975175510.1016/S0002‑9343(02)01379‑7 12517366
     [Google Scholar]
  19. HeckmannJ.G. HeckmannS.M. LangC.J.G. HummelT. Neurological aspects of taste disorders.Arch. Neurol.200360566767110.1001/archneur.60.5.667 12756129
     [Google Scholar]
  20. RademacherW.M.H. AzizY. HielemaA. Oral adverse effects of drugs: Taste disorders.Oral Dis.202026121322310.1111/odi.13199 31532870
     [Google Scholar]
  21. AckermanB.H. KasbekarN. Disturbances of taste and smell induced by drugs.Pharmacotherapy199717348249610.1002/j.1875‑9114.1997.tb03058.x 9165552
     [Google Scholar]
  22. GhaziA. GrantJ.A. Hereditary angioedema: Epidemiology, management, and role of icatibant.Biologics2013710311310.2147/BTT.S27566 23662043
     [Google Scholar]
  23. GriffinH. PearsonS. LinneburS. FixenD. A case of venlafaxine-induced angioedema in an older adult.SAGE Open Med. Case Rep.2021921105046510.1177/2050313X211050465
     [Google Scholar]
  24. UytunM. DemirciE. Angioedema associated with atomoxetine: A case report.Anadolu Psikiyatri Derg.20161733510.5455/apd.220072
     [Google Scholar]
  25. LeungE. Yazbek HannaM. TehamiN. FrancombeJ. Isolated unilateral tongue oedema: The adverse effect of Angiotensin converting enzyme inhibitors.Curr. Drug Saf.20127538238310.2174/157488612805076561 23320432
     [Google Scholar]
  26. JainKK Drug-induced neurological disorders2021
     [Google Scholar]
  27. StoneC.Jr BrownN.J. Angiotensin-converting enzyme inhibitor and other drug-associated angioedema.Immunol. Allergy Clin. North Am.201737348349510.1016/j.iac.2017.04.006 28687104
     [Google Scholar]
  28. SimonsC.T. KleinA.H. CarstensE. Chemogenic Subqualities of Mouthfeel.Chem. Senses201944528128810.1093/chemse/bjz016 31039245
     [Google Scholar]
  29. ShimohataM. WatanabeY. TanakaH. Numbness in the tip of the tongue and lower lip caused by thalamic hemorrhage.J. Stroke Cerebrovasc. Dis.201423355755910.1016/j.jstrokecerebrovasdis.2013.03.021 23602113
     [Google Scholar]
  30. SyedM. ChopraR. SachdevV. Allergic reactions to dental materials- A systematic review.J. Clin. Diagn. Res.2015910ZE04ZE0910.7860/JCDR/2015/15640.6589 26557634
     [Google Scholar]
  31. NobleJ. AhingS.I. KaraiskosN.E. WiltshireW.A. Nickel allergy and orthodontics, a review and report of two cases.Br. Dent. J.2008204629730010.1038/bdj.2008.198 18356874
     [Google Scholar]
  32. KamitaniT. KuroiwaY. HidakaM. Isolated hypesthesia in the right V2 and V3 dermatomes after a midpontine infarction localised at an ipsilateral principal sensory trigeminal nucleus.J. Neurol. Neurosurg. Psychiatry200475101508150910.1136/jnnp.2004.038026 15377715
     [Google Scholar]
  33. BransfieldR. Neuropsychiatric Lyme Borreliosis: An overview with a focus on a specialty psychiatrist’s clinical practice.Healthcare (Basel)20186310410.3390/healthcare6030104 30149626
     [Google Scholar]
  34. LyneA. CreedonA. BaileyB.M.W. Mucosal pigmentation of the hard palate in a patient taking imatinib.BMJ Case Rep20152015bcr201520933510.1136/bcr‑2015‑209335
     [Google Scholar]
  35. MurrayN.P. EchavarríaM. ReculéF. MirandaM. FerresÁ. Acquired hyperpigmentation of the tongue associated with hydroxyurea: Case report of a very rare location of a rare adverse effect.Global J Dermatol Venereol2016411213
     [Google Scholar]
  36. NahhasA.F. BraunbergerT.L. HamzaviI.H. An update on drug-induced pigmentation.Am. J. Clin. Dermatol.2019201759610.1007/s40257‑018‑0393‑2 30374894
     [Google Scholar]
  37. CoustyS. Laurencin-DalicieuxS. Drug-Induced Oral Complications.Cham, SwitzerlandSpringer202110.1007/978‑3‑030‑66973‑7
     [Google Scholar]
  38. LageD. JulianoP.B. MetzeK. SouzaE.M. CintraM.L. Lichen planus and lichenoid drug‐induced eruption: A histological and immunohistochemical study.Int. J. Dermatol.201251101199120510.1111/j.1365‑4632.2011.05113.x 22416968
     [Google Scholar]
  39. KamathV. SetlurK. YerlaguddaK. Oral lichenoid lesions - A review and update.Indian J. Dermatol.201560110210.4103/0019‑5154.147830 25657414
     [Google Scholar]
  40. Braga-SimõesJ. SantosL.A. Linezolide-induced hairy tongue.Oxf. Med. Case Rep.2016201612omw08810.1093/omcr/omw088 28031852
     [Google Scholar]
  41. CecchiC. MarinielloA. CarnioS. DelcuratoloM.D. NovelloS. Black hairy tongue after immune checkpoint inhibitors in NSCLC: A case report and review of the literature.Clin. Lung Cancer2021226e804e80710.1016/j.cllc.2021.03.008 33903029
     [Google Scholar]
  42. HeymannW.R. Psychotropic agent-induced black hairy tongue.Cutis20006612526 10916687
     [Google Scholar]
  43. SivaramanS. Gomathi RadhakrishnanG. ManogaranR. CheriyanB.V. An uncommon side effect of linezolid: Black hairy tongue.Precis. Med. Sci.202110416716910.1002/prm2.12053
     [Google Scholar]
  44. TamamL. AnnagurB.B. Black hairy tongue associated with olanzapine treatment: A case report.Mt. Sinai J. Med.2006736891894 17117318
     [Google Scholar]
  45. NiiyamaY. HaseR. Black hairy tongue caused by metronidazole.Braz. J. Infect. Dis.202125510163310.1016/j.bjid.2021.101633 34634233
     [Google Scholar]
  46. AryalE. RajbhandariM. BhattaraiS. Lansoprazole–induce black hairy tongue-a case report.Nepal Journal of Dermatology. Nepal J Dermatol, Venereol Leprol201715152410.3126/njdvl.v15i1.18054
     [Google Scholar]
  47. PigattoP.D. SpadariF. MeroniL. GuzziG. Black hairy tongue associated with long‐term oral erythromycin use.J. Eur. Acad. Dermatol. Venereol.200822101269127010.1111/j.1468‑3083.2008.02621.x 18331301
     [Google Scholar]
  48. TzikopoulouM. PotolidisE. MandrosC. PerdikouriE.I. Levofloxacin-induced black hairy tongue (BHT) in a 30-year-old female COVID-19 infected patient.Int. J. Case Rep. Imag.2021121410.5348/101264Z01TM2021CR
     [Google Scholar]
  49. SowM.L. MoukafihB. BaldeS. Vinorelbine and carboplatin-induced black tongue: A case report.Therapie202075329730110.1016/j.therap.2019.05.006 31477338
     [Google Scholar]
  50. BozkurtI. YontarE. DoganayM. Black hairy tongue: A rare side effect of linezolid.Nasza Dermatol. Online20123213613710.7241/ourd.20122.30
     [Google Scholar]
  51. LiuY. SungY.F. LiS.Y. An uncommon case of black hairy tongue induced by antibiotics.Am. J. Med. Sci.20213624e31e3210.1016/j.amjms.2021.04.015 33974853
     [Google Scholar]
  52. SakaguchiK. WatariT. Tetracycline‐induced black hairy tongue.J. Gen. Fam. Med.2020213808110.1002/jgf2.300 32489761
     [Google Scholar]
  53. SelvakumarN. Selvapandian ThamizhJ. MenonV. RajkumarR.P. Black hairy tongue (Lingua villosa nigra) in a young male precipitated by Lithium.Asian J. Psychiatr.20162424717210.1016/j.ajp.2016.08.021 27931913
     [Google Scholar]
  54. YamagishiY. MaruyamaK. KobayashiK. Black hairy tongue after chemotherapy for malignant brain tumors.Acta Neurochir. (Wien)2017159116917210.1007/s00701‑016‑3036‑5 27878617
     [Google Scholar]
  55. ShimizuT. TokudaY. Hairy tongue.BMJ Case Rep20122012oct04 1bcr022012575510.1136/bcr‑02‑2012‑5755 23045436
     [Google Scholar]
  56. KuoS. FazelN. Black hairy tongue due to metronidazole.J. Am. Acad. Dermatol.2017766AB5610.1016/j.jaad.2017.04.235
     [Google Scholar]
  57. CoculescuE.C. ŢovaruS. CoculescuB.I. Epidemiological and etiological aspects of burning mouth syndrome.J. Med. Life201473305309 25408745
     [Google Scholar]
  58. López-JornetP. Camacho-AlonsoF. Andujar-MateosP. Sánchez-SilesM. Gómez-GarciaF. Burning mouth syndrome: An update.Med. Oral Patol. Oral Cir. Bucal2010154e562e56810.4317/medoral.15.e562 20038880
     [Google Scholar]
  59. BergdahlM. BergdahlJ. Burning mouth syndrome:Prevalence and associated factors.J. Oral Pathol. Med.199928835035410.1111/j.1600‑0714.1999.tb02052.x 10478959
     [Google Scholar]
  60. AyuseT. OkayasuI. Tachi-YoshidaM. Examination of pain relief effect of Goreisan for glossodynia.Medicine (Baltimore)20209933e2153610.1097/MD.0000000000021536 32872000
     [Google Scholar]
  61. Salort-LlorcaC. Mínguez-SerraM.P. SilvestreF.J. Drug-induced burning mouth syndrome: A new etiological diagnosis.Med. Oral Patol. Oral Cir. Bucal2008133E167E170 18305436
     [Google Scholar]
  62. NettoF.O.G. DinizI.M.A. GrossmannS.M.C. de AbreuM.H.N.G. do CarmoM.A.V. AguiarM.C.F. Risk factors in burning mouth syndrome: A case–control study based on patient records.Clin. Oral Investig.201115457157510.1007/s00784‑010‑0419‑5 20440632
     [Google Scholar]
  63. AzziL. VeronesiG. TagliabueA. Is there an association between drugs and burning mouth syndrome? A case–control study.Oral Dis.20192561634164410.1111/odi.13116 31066953
     [Google Scholar]
  64. AzziL. MantegazzaD. CampioneR. LimidoM. TettamantiL. A new correlation between burning mouth syndrome and drugs.Oncologist2017861
     [Google Scholar]
  65. PalinS.L. KumarS. BarnettA.H. SturdeeD.W. A burning mouth associated with the use of hormone replacement therapy.J. Br. Menopause Soc.20051113810.1258/1362180053654510
     [Google Scholar]
  66. TarkkilaL. LinnaM. TiitinenA. LindqvistC. MeurmanJ.H. Oral symptoms at menopause—the role of hormone replacement therapy.Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.200192327628010.1067/moe.2001.117452 11552144
     [Google Scholar]
  67. BellG.D. PowellK. BurridgeS.M. Experience with‘triple’ anti‐Helicobacter pylori eradication therapy: Side effects and the importance of testing the pre‐treatment bacterial isolate for metronidazole resistance.Aliment. Pharmacol. Ther.19926442743510.1111/j.1365‑2036.1992.tb00556.x 1420735
     [Google Scholar]
  68. JokipiiL. JokipiiA.M.M. Comparison of four dosage schedules in the treatment of giardiasis with metronidazole.Infection197862929410.1007/BF01642166 649204
     [Google Scholar]
  69. Vadhan-RajS. GoldbergJ.D. PeralesM.A. BergerD.P. van den BrinkM.R.M. Clinical applications of palifermin: Amelioration of oral mucositis and other potential indications.J. Cell. Mol. Med.201317111371138410.1111/jcmm.12169 24251854
     [Google Scholar]
  70. SpielbergerR. StiffP. BensingerW. Palifermin for oral mucositis after intensive therapy for hematologic cancers.N. Engl. J. Med.2004351252590259810.1056/NEJMoa040125 15602019
     [Google Scholar]
  71. IngrandI. SolinasM. IngrandP. Lack of effects of simvastatin on smoking cessation in humans: A double-blind, randomized, placebo-controlled clinical study.Sci. Rep.201881383610.1038/s41598‑018‑21819‑7 29497063
     [Google Scholar]
  72. FriedR. [Biochemical studies on a new anti-alcoholic drug, metronidazole (Flagyl)].Arch. Biol. Med. Exp.196937279
     [Google Scholar]
  73. HubicheT. ValenzaB. ChevreauC. FricainJ.C. Del GiudiceP. SibaudV. Geographic tongue induced by angiogenesis inhibitors.Oncologist2013184e16e1710.1634/theoncologist.2012‑0320 23576484
     [Google Scholar]
  74. WaltimoJ. Geographic tongue during a year of oral contraceptive cycles.Br. Dent. J.19911713949610.1038/sj.bdj.4807618 1888590
     [Google Scholar]
  75. OguetaI.C. RamírezM.P. JiménezC.O. CifuentesM.M. Geographic tongue: What a dermatologist should know.Actas Dermo-Sifiliográficas.2019110534134610.1016/j.adengl.2019.05.001 31005233
     [Google Scholar]
  76. DotyR.L. BromleyS.M. Effects of drugs on olfaction and taste.Otolaryngol. Clin. North Am.20043761229125410.1016/j.otc.2004.05.002 15563912
     [Google Scholar]
  77. NatschS. VinksM.H.A.M. VoogtA.K. MeesE.B. MeyboomR.H.B. Anaphylactic reactions to proton-pump inhibitors.Ann. Pharmacother.200034447447610.1345/aph.19235 10772433
     [Google Scholar]
  78. KhanA AungT BhagatR MascarenhasD. Angioedema: An uncommon but potentially life-threatening drug reaction of apixaban.2014
     [Google Scholar]
  79. MahfoozF. AylorK. MathewJ.Jr ReichmuthM. Extending our understanding of exenatide: A rare case of angio-oedema.BMJ Case Rep.2021141e23566310.1136/bcr‑2020‑235663 33461993
     [Google Scholar]
  80. IzzedineH. Interstitial nephritis (first report) in an elderly patient: Case report.Reactions20071163410.2165/00128415‑200711630‑00072
     [Google Scholar]
  81. YounasU. ShafiqO. MansoorS.N. KhalilM.T. Solifenacin-induced acute urticaria and angioedema: A rare adverse effect.Postgrad. Med. J.202298116042042110.1136/postgradmedj‑2020‑138375 33452148
     [Google Scholar]
  82. MilioM. CampanaS. Use of quinolones in the treatment of Pseudomonas aeruginosa infections in children with cystic fibrosis.Pediatr. Med. Chir.199517153
     [Google Scholar]
  83. SokolowskiL. Ukleja-SokolowskaN. Gawronska-UklejaE. Konieczna-BrazisM. BartuziZ. Palacz-DudaV. Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant.Postgrad. Med. J.2022981160420421
     [Google Scholar]
  84. RekstenA. Treatment of Angiotensin-Converting Enzyme Inhibitor-Indced Oropharyngeal Angioedema with Icatibant.2011
     [Google Scholar]
  85. BerheD.F. JuhlinK. StarK. Adverse Drug Reaction reports for cardiometabolic drugs from sub-Saharan Africa: A study in VigiBase.Trop. Med. Int. Health201520679780610.1111/tmi.12481 25704305
     [Google Scholar]
  86. BarreraB.A. WiltonL. HarrisS. ShakirS.A.W. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.Osteoporos. Int.200516121989199810.1007/s00198‑005‑1986‑1 16133643
     [Google Scholar]
  87. DevillierP. FadelR. de BeaumontO. House dust mite sublingual immunotherapy is safe in patients with mild‐to‐moderate, persistent asthma: A clinical trial.Allergy201671224925710.1111/all.12791 26465232
     [Google Scholar]
  88. OlschewskiH. GhofraniH.A. SchmehlT. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial.Ann. Intern. Med.2000132643544310.7326/0003‑4819‑132‑6‑200003210‑00003 10733442
     [Google Scholar]
  89. FinstererJ. ScorzaF.A. Atomoxetine-induced focal seizures with contralateral hypoperfusion and hyper-CKemia.Radiol. Case Rep.202116236937110.1016/j.radcr.2020.11.049 34168713
     [Google Scholar]
  90. ComerH. CardwellK. Brentuximab vedotin infusion reaction management: A case study.J. Adv. Pract. Oncol.201786626629 30310723
     [Google Scholar]
  91. SinghS.K. DitchK. ReddyD.S. SundareshV, Eds. Multiple adverse effects of Denosumab: Management implications in the elderly patients.2017
     [Google Scholar]
  92. HackneyJ. EvansL. Local anaesthetic toxicity in extending epidural top up for caesarean section.Anaesthesia.Nottingham, EnglandWiley2016
     [Google Scholar]
  93. van Pelt-SprangersM.J.M. GeijtemanE.C.T. AlsmaJ. BoereI.A. MathijssenR.H.J. SchuitS.C.E. Oromandibular dystonia: A serious side effect of capecitabine.BMC Cancer201515111510.1186/s12885‑015‑1132‑1 25850956
     [Google Scholar]
  94. LeeK.A. KangH.W. AhnJ.H. SukH.J. KimH. Dysarthria induced by irinotecan in a patient with colorectal cancer.Am. J. Health Syst. Pharm.201370131140114310.2146/ajhp120542 23784161
     [Google Scholar]
  95. ShimadaJ. Early phase II study of doripenem, a new carbapenem antibiotic for injection.Japanese J Chemother2005531435610.11250/chemotherapy1995.53.Supplement1_143
     [Google Scholar]
  96. OkadaH. Basic and clinical studies on doripenem in obstetrics and gynecology.Japenese J Chemother200553Suppl. 1273285
     [Google Scholar]
  97. YingL. QizhangY. DahaiY. Clinical analysis and literature review of 6 cases of burning mouth syndrome-like symptoms caused by the long-term oral administration of omeprazole.J Prev Treat Stomatol Dis202129855310.12016/j.issn.2096‑1456.2021.08.008
     [Google Scholar]
  98. GendreauR.M. ClauwD. GendreauJ. DaughertyB. LedermanS. THU0322 TNX-102 SL for treatment of Fibromyalgia: Approaches to pain measurement.HobokenBMJ Publishing Group Ltd.2015
     [Google Scholar]
  99. JanowskaS. TratkiewiczE. MatlokaM. Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers.Eur. Neuropsychopharmacol.2019291S535S53610.1016/j.euroneuro.2018.11.793
     [Google Scholar]
  100. RanawakaR.R. Patterns of chromonychia during chemotherapy in patients with skin type V and outcome after 1 year of follow-up.Clin. Exp. Dermatol.2009348e920e92610.1111/j.1365‑2230.2009.03713.x20055868
     [Google Scholar]
  101. AcharyaS. PaiK. BhatS. MamathaB. BejadiV. AcharyaS. Oral changes in patients undergoing chemotherapy for breast cancer.Indian J. Dent. Res.201728326126810.4103/ijdr.IJDR_379_1628721989
     [Google Scholar]
  102. OzogD.M. GogstetterD.S. ScottG. GaspariA.A. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid.Arch. Dermatol.200013691133113810.1001/archderm.136.9.113310987869
     [Google Scholar]
  103. BrodyH.J. CohenM. Black tongue secondary to methyldopa therapy.Cutis19863831871883769555
     [Google Scholar]
  104. ThijsJ.C. Van ZwetA.A. OeyH.B. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand. J. Gastroenterol.1993281193493810.3109/003655293090982878284626
     [Google Scholar]
  105. VillaA. AboalelaA. LuskinK.A. CutlerC.S. SonisS.T. WooS.B. PetersonD.E. TreisterN.S. Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease.Biol. Blood Marrow Transplant.201521350350810.1016/j.bbmt.2014.11.68025482865
     [Google Scholar]
  106. RajiyahT. StudyvinS. Bullous Rash, Fever and Conjunctivitis in a Haitian Male.IL, USAAmerican Academy of Pediatrics Elk Grove Village201810.1542/peds.142.1MA5.468
     [Google Scholar]
  107. NathK. VictorR. SharmaS. Eslicarbazepine induced Stevens-Johnson Syndrome: A rare case report.J. Clin. Diagn. Res.2018126VD01VD0310.7860/JCDR/2018/34051.11656
     [Google Scholar]
  108. MignognaM.D. FortunaG. LeuciS. PollioA. RuoppoE. Sunitinib adverse event: Oral bullous and lichenoid mucositis.Ann. Pharmacother.200943354654710.1345/aph.1K59219240256
     [Google Scholar]
  109. KittasV. Oral mucositis in an elderly patient: Case report.Reactions.201314372
     [Google Scholar]
  110. MaierC. [Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor].Anaesthesist1995441287587910.1007/s0010100502258594963
     [Google Scholar]
  111. KaulR. DavidC. SavithaG. RemaJ. RamnarayanB.K. SanjayC.J. ShilpaP.S. Drug induced neutropenia manifesting as oral ulcerations.J. Indian Acad. Oral Med. Radiol.2009212727510.4103/0972‑1363.57890
     [Google Scholar]
  112. KalogirouE.M. TosiosK.I. PiperiE.P. SklavounouA. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.Oral Surg. Oral Med. Oral Pathol. Oral Radiol.20151191e13e1910.1016/j.oooo.2014.08.02325442249
     [Google Scholar]
  113. LakshmiB.S. PatnaikR. ReddyM.H.K. KumarA. JenaA. KumarV.S. Squamous cell carcinoma tongue in a postrenal transplant patient: A case report and review of literature.Indian J. Transplant.201812215610.4103/ijot.ijot_10_18
     [Google Scholar]
  114. McmurdoM.T. HutchisonG. LindsayG. Taste disturbance with acetazolamide.Lancet199033687241190119110.1016/0140‑6736(90)92803‑P1978045
     [Google Scholar]
  115. BriggsE.R. Taste disturbances related to medication use.Consult Pharm.200924753854310.4140/TCP.n.2009.53819689182
     [Google Scholar]
  116. RasmussenE.R. BygumA. ACE-inhibitor induced angio-oedema treated with complement C1-inhibitor concentrate.BMJ Case Rep.2013201304 1bcr201320065210.1136/bcr‑2013‑20065224096073
     [Google Scholar]
  117. AleidW. SidebottomA. Oral Mucosal irritation with incorrect use of alendronate.Br. J. Oral Maxillofac. Surg.200947217017110.1016/j.bjoms.2008.08.00518814944
     [Google Scholar]
  118. GopalrajR. Alendronic acid Glossodynia after administration of crushed.Reactions.200912521610.2165/00128415‑200912520‑00018
     [Google Scholar]
  119. JanaT. Geographic tongue and glossodynia in an elderly patient: Case report.Reactions.201113711
     [Google Scholar]
  120. CheX. LiY. FangY. ReisC. WangH. Antiarrhythmic drug-induced smell and taste disturbances.Medicine (Baltimore)20189729e1111210.1097/MD.000000000001111230024498
     [Google Scholar]
  121. SadasivamB. JhajR. Dysgeusia with amlodipine – a case report.Br. J. Clin. Pharmacol.200763225310.1111/j.1365‑2125.2006.02727.x17274793
     [Google Scholar]
  122. NoorT.N.E.T.A. Burning mouth syndrome caused by xerostomia secondary to amlodipine.Dent. J.202053418719010.20473/j.djmkg.v53.i4.p187‑190
     [Google Scholar]
  123. SheikhZ. KhanA.S. KhanS. Lingua villosa nigra.Lancet20113779772118310.1016/S0140‑6736(10)60930‑021440293
     [Google Scholar]
  124. SundarS. BurgeF. Geographical tongue induced by axitinib.BMJ Case Rep.20152015bcr201521131810.1136/bcr‑2015‑21131826475876
     [Google Scholar]
  125. GavrilovicI.T. BalagulaY. RosenA.C. RamaswamyV. DicklerM.N. DunkelI.J. LacoutureM.E. Characteristics of oral mucosal events related to bevacizumab treatment.Oncologist201217227427810.1634/theoncologist.2011‑019822282905
     [Google Scholar]
  126. Martinez-GarciaM. Roman-SainzJ. Silvestre-TornerN. Tabbara CarrascosaS. Bevacizumab-induced geographic tongue.Dermatol. Pract. Concept.2021113202104310.5826/dpc.1103a4334414004
     [Google Scholar]
  127. IoffredaM.D. GordonC.A. AdamsD.R. NaidesS.J. MillerJ.J. Black tongue.Arch. Dermatol.2001137796896911453829
     [Google Scholar]
  128. PatelN. HarviewC.L. HsiaoJ.L. Asymptomatic transient lingual hyperpigmentation.Cutis20201056288293, 29310.12788/cutis.000132716992
     [Google Scholar]
  129. TreisterN.S. RichardsonP. SchlossmanR. MillerK. WooS.B. Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws.Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.20081056e1e410.1016/j.tripleo.2008.02.01018417376
     [Google Scholar]
  130. TackettA.E. SmithK.M. Bupropion-induced angioedema.Am. J. Health Syst. Pharm.200865171627163010.2146/ajhp07057518714109
     [Google Scholar]
  131. ChenC. ChevrotD. ContaminC. RomanetT. AllenetB. MallaretM. [Stomatitis and ageusia induced by candesartan].Nephrologie2004253979915185557
     [Google Scholar]
  132. VillalónG. MartínJ.M. PinazoM.I. CalduchL. AlonsoV. JordáE. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.Am. J. Clin. Dermatol.200910426126310.2165/00128071‑200910040‑0000619489659
     [Google Scholar]
  133. VasudevanB. An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?Indian J. Pharmacol.201042532632810.4103/0253‑7613.7040121206630
     [Google Scholar]
  134. JZ. EmA-G. Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine.J. Cancer Res. Ther. (Manch.)201311022622910.14312/2052‑4994.2013‑34
     [Google Scholar]
  135. VlassesP.H. RotmenschH.H. FergusonR.K. SheafferS.L. “Scalded mouth” caused by angiotensin-converting-enzyme inhibitors.BMJ198228463301672167310.1136/bmj.284.6330.16726282382
     [Google Scholar]
  136. JacksonB. MaherD. MatthewsP.G. McGRATHB.P. JohnstonC.I. Lack of cross sensitivity between captopril and enalapril.Aust. Med.1988181212710.1111/j.1445‑5994.1988.tb02234.x2840055
     [Google Scholar]
  137. JohnsonT.M. JohnsonT.M. Captopril Glossopyrosis.Arch. Dermatol.1989125101437143810.1001/archderm.1989.016702201350292679406
     [Google Scholar]
  138. ZazgornikJ. KaiserW. BiesenbachG. Captopril-induced dysgeusia.Lancet19933418859154210.1016/0140‑6736(93)90686‑B8099421
     [Google Scholar]
  139. BrownR.S. KrakowA.M. DouglasT. ChoksiS.K. “Scalded mouth syndrome” caused by angiotensin converting enzyme inhibitors.Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.199783666566710.1016/S1079‑2104(97)90316‑49195620
     [Google Scholar]
  140. ObaraT. NaitoH. NojimaT. KogaH. NakaoA. Burning mouth syndrome induced by angiotensin-converting enzyme inhibitors.Cureus20201211e1137610.7759/cureus.1137633312778
     [Google Scholar]
  141. Yi-ChunL. Black tongue.Eur. J. Intern. Med.201848e1e210.1016/j.ejim.2017.07.00128712574
     [Google Scholar]
  142. PathakA. PandeyA. MishraA. MishraA. Cefuroxime axetil induced glossitis: A case report.Int. J. Basic Clin. Pharmacol.20143472973210.5455/2319‑2003.ijbcp20140809
     [Google Scholar]
  143. BlayaM. SabaN. Images in clinical medicine. Chemotherapy-induced hyperpigmentation of the tongue.N. Engl. J. Med.201136510e2010.1056/NEJMicm101426821899446
     [Google Scholar]
  144. TuccoriM. Clarithromycin/levofloxacin/sunitinib taste and smell alterations: 5 case reports.Reactions201113752910.2165/00128415‑201113750‑00034
     [Google Scholar]
  145. AlfreijatM. Tongue hyperpigmentation associated with chemotherapy.J. Community Hosp. Intern. Med. Perspect.201333-42104710.3402/jchimp.v3i3‑4.2104724392209
     [Google Scholar]
  146. CasamiquelaK.M. CohenP.R. Chemotherapy-associated tongue hyperpigmentation and blue lunula.J. Drugs Dermatol.201312222322623377398
     [Google Scholar]
  147. StringerL.L. ZitellaL. Hyperpigmentation of the tongue.J. Adv. Pract. Oncol.201451717225032039
     [Google Scholar]
  148. ParvaeiP. MortazaviH. BaharvandM. Severe pigmentation of oral mucosa, skin and nails due to breast cancer chemotherapy–case report.Dent. Med. Probl.2015523363365
     [Google Scholar]
  149. CoM.L. EstebanM.J. Lingual hyperpigmentation after 5-fluorouracil chemotherapy.BMJ Case Rep.2017201721980610.1136/bcr‑2017‑21980628433985
     [Google Scholar]
  150. ImanM. Tongue hyperpigmentation induced by cyclophosphamide and doxorubicin: Case report.Am J Biomed Sci. Res.202114300199210.34297/AJBSR.2021.14.001992
     [Google Scholar]
  151. RupertK.L. AhmadR. BrufskyA.M. NasrazadaniA. Doxorubicin induced tongue hyperpigmentation.Curr. Prob. Cancer: Case Rep.2022510014710.1016/j.cpccr.2022.100147
     [Google Scholar]
  152. RosenS. TrefflichD. RosenM.A. Probable clindamycin-induced ageusia, xerostomia, and burning mouth syndrome.Ann. Pharmacother.2012467-81119112010.1345/aph.1R23422764332
     [Google Scholar]
  153. CulhaneN.S. HodleA.D. Burning mouth syndrome after taking clonazepam.Ann. Pharmacother.2001357-887487610.1345/aph.1Z43411485137
     [Google Scholar]
  154. IliasI. VenakiE. NikopoulouS. KochC.A. Glossodynia after osteoporosis treatment.Am. J. Med. Sci.2017353550250310.1016/j.amjms.2016.08.01228502340
     [Google Scholar]
  155. IshimaruT. YokogawaH. Olfactory and gustatory disturbances caused by digitalism: A case report.Auris Nasus Larynx200633446546910.1016/j.anl.2006.03.00416730151
     [Google Scholar]
  156. BermanJL Dysomia, dysgeusia, and diltiazem.Ann Intern Med.1985102571710.7326/0003‑4819‑102‑5‑717_2
     [Google Scholar]
  157. IvesT.J. StewartR.B. Doxepin-induced acute glossitis.Am. J. Health Syst. Pharm.198037111551155210.1093/ajhp/37.11.15517211862
     [Google Scholar]
  158. RamsakalA MangatL. Lingua villosa nigra.New Eng. J. Med.200735723238810.1056/NEJMicm065655
     [Google Scholar]
  159. Dilİ.B.S.K. Drug-induced black hairy tongue: A case report.Mediterr J Infect Microbes Antimicrob.20132513
     [Google Scholar]
  160. YoshidaK. FukuchiT. SugawaraH. Dysosmia and dysgeusia associated with duloxetine.BMJ Case Rep.2017201710.1136/bcr‑2017‑22247029170185
     [Google Scholar]
  161. Borrás-BlascoJ. BeldaA. Rosique-RoblesJ.D. CasteráM.D.E. AbadF.J. Burning mouth syndrome due to efavirenz therapy.Ann. Pharmacother.2006407-81471147210.1345/aph.1H03616822896
     [Google Scholar]
  162. TriantosD. KanakisP. Stomatodynia (burning mouth) as a complication of enalapril therapy.Oral Dis.200410424424510.1111/j.1601‑0825.2004.01002.x15196148
     [Google Scholar]
  163. CastellsX. RodoredaI. PedrósC. CerezaG. LaporteJ-R. Drug points: Dysgeusia and burning mouth syndrome by eprosartan.BMJ20023257375127710.1136/bmj.325.7375.127712458247
     [Google Scholar]
  164. JeongJ.S. LeeJ.Y. KimM.K. YoonT.Y. Black hairy tongue associated with erlotinib treatment in a patient with advanced lung cancer.Ann. Dermatol.201123452652810.5021/ad.2011.23.4.52622148027
     [Google Scholar]
  165. ChauhanA. PraharajS.K. Escitalopram-associated tongue hypoesthesia.J. Clin. Psychopharmacol.202141334634710.1097/JCP.000000000000136833657072
     [Google Scholar]
  166. PatanèM. IsolaS. GangemiS. MinciulloP.L. Mucosal exfoliation as a selective reaction to etoricoxib.J. Clin. Pharm. Ther.201641672272410.1111/jcpt.1244527576781
     [Google Scholar]
  167. LevensonJ.L. Burning mouth syndrome as a side effect of SSRIs.J. Clin. Psychiatry200364333633710.4088/JCP.v64n0317b12716278
     [Google Scholar]
  168. RaghavanS.A. PuttaswamiahR.N. BirurP.N. RamaswamyB. SunnyS.P. Antidepressant-induced burning mouth syndrome: A unique case.Korean J. Pain201427329429610.3344/kjp.2014.27.3.29425031818
     [Google Scholar]
  169. AroraR.D. PrabhaN. SinghN. NagarkarN. Glycopyrrolate-induced black hairy tongue.Indian Dermatol. Online J.202011225625710.4103/idoj.IDOJ_54_1932477994
     [Google Scholar]
  170. LaughonS.K. ShinnL.L. NunleyJ.R. Melanonychia and mucocutaneous hyperpigmentation due to hydroxyurea use in an HIV‐infected patient.Int. J. Dermatol.2000391292893110.1046/j.1365‑4362.2000.00988‑2.x11168664
     [Google Scholar]
  171. PaleriV. LindseyL. Oral ulcers caused by hydroxyurea.J. Laryngol. Otol.20001141297697710.1258/002221500190451811177373
     [Google Scholar]
  172. IssaivananM. MituP.S. ManishaC. PraveenK. Cutaneous manifestations of hydroxyurea therapy in childhood: Case report and review.Pediatr. Dermatol.200421212412710.1111/j.0736‑8046.2004.21207.x15078351
     [Google Scholar]
  173. LopesM.A. MendonçaR. CapellaroK. GueirosL.A. PinheiroV.R.P. Oral lesions associated with hydroxyurea treatment.Indian J. Dent. Res.201122686987010.4103/0970‑9290.9469022484890
     [Google Scholar]
  174. NofalA. El-DinE.S. Hydroxyurea‐induced dermatomyositis: True amyopathic dermatomyositis or dermatomyositis‐like eruption?Int. J. Dermatol.201251553554110.1111/j.1365‑4632.2011.05105.x22515579
     [Google Scholar]
  175. BadawiM. AlmazrooaS. AzherF. AlsayesF. Hydroxyurea-induced oral ulceration.Oral Surg. Oral Med. Oral Pathol. Oral Radiol.20151206e232e23410.1016/j.oooo.2015.09.00626548732
     [Google Scholar]
  176. MudawiD. NashwanA.J. GameelA. FareedS. AbdullaM. YassinM.A. Rare oral mucosal manifestations of hydroxyurea therapy in Chronic Myeloid Leukemia.Haematology Int. J.20171200010710.23880/HIJ‑16000107
     [Google Scholar]
  177. NeculiseanuE. HarewoodJ. SidhuG. Hydroxyurea-induced tongue hypermelanosis and transverse melanonychia.Cureus20191112e631110.7759/cureus.631131938603
     [Google Scholar]
  178. Veillet-LemayG. HaberR.M. Hydroxyurea-induced oral hyperpigmentation: A case report and review of the literature.J. Cutan. Med. Surg.201923111111310.1177/120347541880307430232899
     [Google Scholar]
  179. AlshammasiB. AlbasryZ. MeshikhesF. Oral hyperpigmentation associated with hydroxyurea in a patient with polycythemia vera: A case report.Clin. Case Rep.20208101904190910.1002/ccr3.301233088516
     [Google Scholar]
  180. ZhaoS. FanL. FengJ. MaP. Reversible black tongue: A little known side effect of imipenem/cilastatin and evidence for novel mode of action.J. Clin. Pharm. Ther.202045237037210.1111/jcpt.1306631621928
     [Google Scholar]
  181. WillemsM. MunteK. VrolijkJ.M. den HollanderJ.C. BöhmM. KemmerenM.H. de ManR.A. BrouwerJ.T. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.Br. J. Dermatol.2003149239039410.1046/j.1365‑2133.2003.05422.x12932249
     [Google Scholar]
  182. GurgutaC. KauerC. BergholzU. FormannE. Steindl-MundaP. FerenciP. Tongue and skin hyperpigmentation during PEG-interferon-α/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.Am. J. Gastroenterol.2006101119719810.1111/j.1572‑0241.2005.00323.x16405555
     [Google Scholar]
  183. TorresH.A. BullL. ArduinoR.C. BarnettB.J. Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.Am. J. Gastroenterol.200710261334133510.1111/j.1572‑0241.2007.01162.x17531028
     [Google Scholar]
  184. MayetA.Y. Loss of smell (anosmia) and taste (ageusia) in a patient treated with pegylated interferon alfa and ribavirin.Curr. Ther. Res. Clin. Exp.200768427127710.1016/j.curtheres.2007.08.00624683217
     [Google Scholar]
  185. FernándezA. VázquezS. Rodríguez-GonzálezL. Tongue hyperpigmentation resulting from peginterferon alfa‐2a and ribavirin treatment in a Caucasian patient with chronic hepatitis C.J. Eur. Acad. Dermatol. Venereol.200822111389139110.1111/j.1468‑3083.2008.02653.x18355209
     [Google Scholar]
  186. de MoraesP.C. NoceC.W. ThomazL.A. MautoniM.C. CorrêaM.E.P. Tongue hyperpigmentation resulting from peginterferon alfa and ribavirin combination therapy: A case report.J. Am. Dent. Assoc.2009140111377137910.14219/jada.archive.2009.007319884395
     [Google Scholar]
  187. KrishnaYR IthaS What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?Liver Int201030341610.1111/j.1478‑3231.2009.02025.x
     [Google Scholar]
  188. FarshidiD. ChiuM.W. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.J. Am. Acad. Dermatol.201062116416510.1016/j.jaad.2009.03.02120082904
     [Google Scholar]
  189. KarabayO. GöksügürN. ÖğütlüA. Tongue hyperpigmentation during interferon therapy.J. Dermatol.201138329029110.1111/j.1346‑8138.2010.01022.x21342236
     [Google Scholar]
  190. GhoshS. DusejaA. DhimanR.K. ChawlaY.K. Tongue hyperpigmentation resulting from peginterferon alfa-2b and ribavirin treatment in a patient with chronic hepatitis C.Dig. Dis. Sci.201257382082110.1007/s10620‑011‑1914‑521948358
     [Google Scholar]
  191. Tavakoli-TabasiS. BagreeA. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.J. Clin. Gastroenterol.201246216216710.1097/MCG.0b013e318228b5f621814144
     [Google Scholar]
  192. BachmeyerC PellenJ-C Tongue hyperpigmentation during hepatitis C treatment.CMAJ201218413149810.1503/cmaj.111985
     [Google Scholar]
  193. ElghonemyK. ChristianC. WeisenreiderJ. DowneyM. HemakH. Purple Tongue; A rare side effect resulting from Peginterferon Alfa 2-A and Ribavirin treatment in a patient with chronic Hepatitis C.Am. J. Gastroenterol.2012107S412S41310.14309/00000434‑201210001‑01016
     [Google Scholar]
  194. MlikaR.B. KerkeniN. MarrakH. FennicheS. MokhtarI. DebbicheA. Tongue hyperpigmentation during PEG‐interferon‐alfa/ribavirin therapy in a non‐Caucasian patient with chronic hepatitis C: A case report and review of the literature.Int. J. Dermatol.201352564364410.1111/j.1365‑4632.2011.04921.x23046405
     [Google Scholar]
  195. ArabJ.P. VargasJ.I. MoralesC. ArreseM. Black hairy tongue during interferon therapy for hepatitis C.Ann. Hepatol.201514341441510.1016/S1665‑2681(19)31282‑725864223
     [Google Scholar]
  196. AlyouzbakiA.Z. KhatibA. ShennakM.M. SneinehA.A. Al BdourM.D. Tongue hyperpigmentation during interferon and ribavirin therapy : A case report.Al-Magallat al-Tibbiyyat al-Urdunniyyat201650420921510.12816/0035057
     [Google Scholar]
  197. KasuyaY. YamaguchiS. YamamotoY. UezatoH. TakahashiK. Glossal pigmentation caused by the simultaneous uptake of iron and tea.Eur. J. Dermatol.201424449349410.1684/ejd.2014.237124897922
     [Google Scholar]
  198. HeiseE. SchnuchA. Taste and olfactory disturbances after treatment for acne with isotretinoin, a 13-cis-isomer of retinoic acid.Eur. Arch. Otorhinolaryngol.1990247638238310.1007/BF001790132149010
     [Google Scholar]
  199. SakalliogluO. Black tongue due to lansoprazole plus metronidazole.Indian Pediatr.201451976310.1007/s13312‑014‑0500‑225228624
     [Google Scholar]
  200. ChenT.H. YuH.T. WuC.H. LinC.C. Black hairy tongue in an end-stage renal disease patient.J. Formos. Med. Assoc.202112071531153210.1016/j.jfma.2020.12.01733388236
     [Google Scholar]
  201. BloomM.D. GibneyJ.M. HeldermonC.D. Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: A case report.Cancer Treat. Commun.201671310.1016/j.ctrc.2016.02.00627110490
     [Google Scholar]
  202. KalogirouE.M. KatsoulasN. TosiosK.I. LazarisA.C. SklavounouA. Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?J. Clin. Exp. Dent.201792010.4317/jced.5342828210457
     [Google Scholar]
  203. CoonE.A. LaughlinR.S. Burning mouth syndrome in Parkinson’s disease: Dopamine as cure or cause?J. Headache Pain201213325525710.1007/s10194‑012‑0421‑122322657
     [Google Scholar]
  204. Murray-BrownF.L. A case of possible glossitis in a patient with non small cell carcinoma of the lung secondary to levomepromazine.Palliat. Med.201226686086110.1177/026921631143495322918478
     [Google Scholar]
  205. AmirK.A. BobbaR.K. ClarkeB. Nagy-AgrenS. ArsuraE.L. BalogunS.A. EvansJ.M. Tongue discoloration in an elderly kidney transplant recipient: Treatment-related adverse event?Am. J. Geriatr. Pharmacother.20064326026310.1016/j.amjopharm.2006.09.00117062327
     [Google Scholar]
  206. RefaatM. HyleE. MalhotraR. SeidmanD. DeyB. Linezolid-induced lingua villosa nigra.Am. J. Med.20081216e110.1016/j.amjmed.2008.02.02318501207
     [Google Scholar]
  207. MaJ.S. Teeth and tongue discoloration during linezolid therapy.Pediatr. Infect. Dis. J.200928434534610.1097/INF.0b013e318199332f19238109
     [Google Scholar]
  208. Jover-DiazF. Cuadrado-PastorJ.M. Talents-BolosA. Martin-GonzalezC. Black tongue associated with linezolid.Am. J. Ther.2010174e115e11710.1097/MJT.0b013e3181a59bcd20634649
     [Google Scholar]
  209. MarinaV.P. KasmaniR. An uncommon side-effect of linezolid.Int. Urol. Nephrol.201244399599610.1007/s11255‑011‑0005‑z21643927
     [Google Scholar]
  210. KhasawnehF.A. MotiD.F. ZorekJ.A. Linezolid-induced black hairy tongue: A case report.J. Med. Case Reports2013714610.1186/1752‑1947‑7‑4623414605
     [Google Scholar]
  211. PetropoulouT. LagonaE. SyriopoulouV. MichosA. Teeth and tongue discoloration after linezolid treatment in children.Pediatr. Infect. Dis. J.201332111284128510.1097/INF.0b013e3182a5c42b23934205
     [Google Scholar]
  212. AijaziI. AbdullaF.M. Linezolid induced black hairy tongue: A rare side effect.J. Ayub Med. Coll. Abbottabad201426340140325671958
     [Google Scholar]
  213. MaharaniB. ParthasarathiT. RavichandranV. BalajiG. Linezolid induced black hairy tongue.Indian J. Pharmacol.201446665365410.4103/0253‑7613.14494225538341
     [Google Scholar]
  214. RajR.T. RajR. NagpalJ. KumarR. Linezolid induced black hairy tongue an uncommon phenomenon: A case report with update of review of literature.Am J Med Sci Med.20164717610.12691/ajmsm‑4‑4‑1
     [Google Scholar]
  215. JainA.K. PuriM.M. SarinR. Black brown discoloration and hairy tongue – A rare linezolid side effect.Indian J. Tuberc.2017641444610.1016/j.ijtb.2016.06.00328166916
     [Google Scholar]
  216. BraggioC. BocchialiniG. VenturaL. CarbognaniP. RuscaM. AmpolliniL. Linezolid-induced black hairy tongue.Acta Biomed.201889340841010.23750/abm.v89i3.706030333468
     [Google Scholar]
  217. RaoA AparnaK ReddyV FarheenS HakkaniR ParimalaD Linezolid-induced black pigmentation of tongue and perioral region.Indian J. Paediatr. Dermatol.201920218919010.4103/ijpd.IJPD_24_18
     [Google Scholar]
  218. LuoS. LuoQ. GaoX. LiJ. Adverse reaction report and retrospective analysis of black hairy tongue caused by linezolid.Respir. Med. Case Rep.20203110115910.1016/j.rmcr.2020.10115932944496
     [Google Scholar]
  219. KarthikeyanK. IswaryaA. Linezolid-induced black hairy tongue.Indian J Drugs Dermatol.20217210410.4103/ijdd.ijdd_48_20
     [Google Scholar]
  220. ChavandaS. GuptaM. DholeT. Black hairy tongue associated with linezolid therapy in a patient with mycobacterial abscesses infection- Report from rural india.Int. J. Infect. Dis.202010117510.1016/j.ijid.2020.09.470
     [Google Scholar]
  221. LeeJ. ChungH.S. RohJ. OhY. MokJ. Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report.Sci. Prog.2021104310.1177/0036850421104298234541939
     [Google Scholar]
  222. SavinoL.B. HaushalterN.M. Lisinopril-induced “scalded mouth syndrome”.Ann. Pharmacother.199226111381138210.1177/1060028092026011091335803
     [Google Scholar]
  223. PatkiA.H. Geographic tongue developing in a patient on lithium carbonate therapy.Int. J. Dermatol.199231536836910.1111/j.1365‑4362.1992.tb03966.x1587672
     [Google Scholar]
  224. NathanK.I. Development of mucosal ulcerations with lithium carbonate therapy.Am. J. Psychiatry19951526956b95710.1176/ajp.152.6.956b7755137
     [Google Scholar]
  225. GraciousB.L. LlanaM. BartonD.D. Lithium and geographic tongue.J. Am. Acad. Child Adolesc. Psychiatry19993891069107010.1097/00004583‑199909000‑0000510504802
     [Google Scholar]
  226. TeraoT. WatanabeS. HoakiN. HoakiT. Strange taste and mild lithium intoxication.BMJ Case Rep.2011201110.1136/bcr.05.2011.426722689608
     [Google Scholar]
  227. ChenW-Y. ChenA-C. TsaiS-J. LinJ-J. Reversible oro-lingual dyskinesia related to lithium intoxication.Acta Neurol. Taiwan.2013221323523479244
     [Google Scholar]
  228. de CooI.F. HaanJ. Long lasting impairment of taste and smell as side effect of lithium carbonate in a cluster headache patient.Headache20165671201120310.1111/head.1287227317012
     [Google Scholar]
  229. HanyuS. SugitaN. MatsudaM. MuraiT. FujiwaraH. Lithium intoxication–induced dysgeusia accompanied by glossalgia in a patient receiving lithium carbonate: A case report.J. Med. Case Rep.202014114910.1186/s13256‑020‑02495‑632907624
     [Google Scholar]
  230. BonnetU. RingelP. Black hairy tongue associated with lorazepam treatment of a male smoker with major depression.J. Clin. Psychopharmacol.201737226126310.1097/JCP.000000000000066128129309
     [Google Scholar]
  231. SchliengerR. SaxerM. HaefeliW. Reversible ageusia associated with losartan.Lancet1996347899947147210.1016/S0140‑6736(96)90047‑18618505
     [Google Scholar]
  232. HeeringaM. van PuijenbroekE.P. Reversible dysgeusia attributed to losartan.Ann. Intern. Med.199812917210.7326/0003‑4819‑129‑1‑199807010‑000239653007
     [Google Scholar]
  233. OhkoshiN ShojiS Reversible ageusia induced by losartan: A case report.Eur J Neurol.20029331510.1046/j.1468‑1331.2002.00389.x
     [Google Scholar]
  234. DeemingG.M.J. CollingwoodJ. PembertonM.N. Methotrexate and oral ulceration.Br. Dent. J.20051982838510.1038/sj.bdj.481197215702101
     [Google Scholar]
  235. TroeltzschM. von BlohnG. KriegelsteinS. WoodlockT. GasslingV. BerndtR. TroeltzschM. Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: Report of 2 cases and literature review.Oral Surg. Oral Med. Oral Pathol. Oral Radiol.20131155e28e3310.1016/j.oooo.2012.12.00823601229
     [Google Scholar]
  236. WilliamsB.G. Oral drug reaction to methyldopa.Oral Surg. Oral Med. Oral Pathol.198356437537710.1016/0030‑4220(83)90347‑X6579477
     [Google Scholar]
  237. De La FuenteJ.R. BerlangaC. Glossitis associated with mianserin.Lancet1984323837023310.1016/S0140‑6736(84)92160‑36141376
     [Google Scholar]
  238. LeibovitchG. MaaraviY. ShalevO. Severe facial oedema and glossitis associated with mianserin.Lancet1989334866787187210.1016/S0140‑6736(89)93045‑62571803
     [Google Scholar]
  239. YoungT.M. MathiasC.J. Taste and smell disturbance with the α-adrenoceptor agonist midodrine.Ann. Pharmacother.200438111868187010.1345/aph.1E17115466905
     [Google Scholar]
  240. KatzJ BarakS ShemerJ LangevitzP LivnehA Black tongue associated with minocycline therapy.Arch Dermatol.1995131562010.1001/archderm.1995.01690170124028
     [Google Scholar]
  241. MeyersonM.A. CohenP.R. HymesS.R. Lingual hyperpigmentation associated with minocycline therapy.Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.199579218018410.1016/S1079‑2104(05)80279‑37614181
     [Google Scholar]
  242. TanziE.L. HeckerM.S. Minocycline-induced hyperpigmentation of the tongue.Arch. Dermatol.2000136342742810.1001/archderm.136.3.42710724219
     [Google Scholar]
  243. FilitisD.C. GraberE.M. Minocycline-induced hyperpigmentation involving the oral mucosa after short-term minocycline use.Cutis2013921464823961526
     [Google Scholar]
  244. ImafukuK. NatsugaK. AoyagiS. ShimizuH. Mucosal hyperpigmentation from prophylactic minocycline for EGFR inhibitor.J. Eur. Acad. Dermatol. Venereol.201630469069210.1111/jdv.1297825627561
     [Google Scholar]
  245. HamadY. WarrenD.K. Black hairy tongue.N. Engl. J. Med.201837910e1610.1056/NEJMicm180035130184449
     [Google Scholar]
  246. MouraM.D.G. SennaM.I.B. MadureiraD.F. FonsecaL.M.S. MesquitaR.A. Oral adverse effects due to the use of Nevirapine.J. Contemp. Dent. Pract.200891849010.5005/jcdp‑9‑1‑8418176653
     [Google Scholar]
  247. HealyC.M. SmythY. FlintS.R. Persistent nicorandil induced oral ulceration.Br. Heart J.2004907e3810.1136/hrt.2003.03183115201264
     [Google Scholar]
  248. LevensonJ.L. Dysomia, dysgeusia, and nifedipine.Ann. Intern. Med.1985102113513610.7326/0003‑4819‑102‑1‑135_2
     [Google Scholar]
  249. OlsufkaW. CabralD. McArdleM. KavanaghR. Nortriptyline-induced oral ulceration: A case report.Ment. Health Clin.20188630931210.9740/mhc.2018.11.30930397573
     [Google Scholar]
  250. JhajR. GourP. AsatiD. Black hairy tongue with a fixed dose combination of olanzapine and fluoxetine.Indian J. Pharmacol.201648331832010.4103/0253‑7613.18289427298505
     [Google Scholar]
  251. GiriV.P. KanodiaS. VeerabhadrappaR. GiriO. ShankarV. Black hairy tongue with olanzapine: A rare case report.Indian J. Psychiatry201759224925010.4103/psychiatry.IndianJPsychiatry_289_1628827881
     [Google Scholar]
  252. GiriV.P. DattaD. DeviP. Olanzapine-induced black hairy tongue: A rare case.Int. J. Basic Clin. Pharmacol.201768209110.18203/2319‑2003.ijbcp20173302
     [Google Scholar]
  253. LongS. ChenY. ShiJ. TianJ. NiJ. Black hairy tongue associated with olanzapine use in a female dementia patient.J. Clin. Psychopharmacol.202242221121410.1097/JCP.000000000000150334935654
     [Google Scholar]
  254. CamkurtM.A. MetinM.S. SonmezE.O. Black hairy tongue probably related to paroxetine use: A case report.Klinik Psikofarmakol. BBülteni201525440340610.5455/bcp.20150707104145
     [Google Scholar]
  255. GilmoreG. QamarS. ChaudharyU.B. Geographic tongue (benign migratory glossitis) in a patient treated with Pazopanib for metastatic renal cell carcinoma.Cancer Treat. Commun.201661310.1016/j.ctrc.2016.01.002
     [Google Scholar]
  256. NeweyC.R. WiscoD. NattanmaiP. SarwalA. Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus.Ther. Adv. Drug Saf.20167519520310.1177/204209861665941427695621
     [Google Scholar]
  257. RenJ. ZhengY. DuH. WangS. LiuL. DuanW. ZhangZ. HengL. YangQ. Antibiotic-induced black hairy tongue: Two case reports and a review of the literature.J. Int. Med. Res.2020481010.1177/030006052096127933044871
     [Google Scholar]
  258. IsikS.R. KarakayaG. ErkinG. KalyoncuA.F. Multidrug-induced erythema multiforme.J. Investig. Allergol. Clin. Immunol.200717319619817583109
     [Google Scholar]
  259. PinheiroT.N. FayadF. JúniorL.R.M. NichthauserB. BragaF. PassosS.M. Palatal perforation and chemical ulcers of the tongue in a blind patient.Spec. Care Dentist.201737525325710.1111/scd.1223528833282
     [Google Scholar]
  260. MarcottM. FarkasA. KorenoskiA. LynchM. Ingestion of denture cleansing tablets resulting in severe airway edema and fatal respiratory arrest.Clin. Toxicol.2018201824
     [Google Scholar]
  261. UğurS. KaçarC. Prednisolone-induced hairy tongue: A case report.Arch. Rheumatol.201934334835110.5606/ArchRheumatol.2019.723931598603
     [Google Scholar]
  262. GautamM. PatelS. SablabanI. SivananthanM. Burning mouth syndrome.J. Clin. Psychopharmacol.202141449950010.1097/JCP.000000000000141334166257
     [Google Scholar]
  263. VázquezPG This girl is on fire.Eur. Psych.202164S1S24610.1192/j.eurpsy.2021.660
     [Google Scholar]
  264. MaierC. Lebensbedrohliches postoperatives Angiodem nach Einnahme von ACE-Hemmern.Anaesthesist1995441287587910.1007/s0010100502258594963
     [Google Scholar]
  265. HoP. KalicinskyC. Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant. Allergy Asthma Clin Immunol.Ottawa, ON, CanadaSpringer2014
     [Google Scholar]
  266. WilliamsM. HatipogluB. Development of Abnormal Pigmentation of the Oral Mucosa Following Adjuvant Radioactive Iodine Treatment.AACE Clin. Case Rep.201622e113e11610.4158/EP15670.CR
     [Google Scholar]
  267. AlencarR.C. CobasR.A. GomesM.B. Allergic reaction related to ramipril use: A case report.Diabetol. Metab. Syndr.201021410.1186/1758‑5996‑2‑420180980
     [Google Scholar]
  268. BorasV. BrailoV. JurasD.V. Ramipril Induced Burning Mouth Symptoms.Annu. Res. Rev. Biol.20144243945394810.9734/ARRB/2014/10308
     [Google Scholar]
  269. HahnJ. TrainottiS. HoffmannT.K. GreveJ. Drug-induced inhibition of angiotensin converting enzyme and dipeptidyl peptidase 4 results in nearly therapy resistant bradykinin induced angioedema: A case report.Am. J. Case Rep.20171857657910.12659/AJCR.90196028539578
     [Google Scholar]
  270. AkcaboyM. SahinS. ZorluP. ŞenelS. Ranitidine‐induced black tongue: A case report.Pediatr. Dermatol.2017346e334e33610.1111/pde.1330928967681
     [Google Scholar]
  271. NislyS.A. KaraA. KnightT.B. Simvastatin: A risk factor for angioedema?J. Pharm. Technol.201329314915210.1177/875512251302900309
     [Google Scholar]
  272. KimA. Sorafenib and Sunitinib.Oncologist2009148800805
     [Google Scholar]
  273. IshiiN. KawanoY. SuzukiM. KomodaM. MakinoK. HanawaT. Effects of a camostat mesilate gargle on stomatitis caused by molecular target therapy: A case report.Jpn J Pharm Palliat Care Sci.2016938791
     [Google Scholar]
  274. TeixeiraV VieiraR FigueiredoA. Tegafur-induced acral hyperpigmentation.Dermatol. Rep.201132e3010.4081/dr.2011.e30
     [Google Scholar]
  275. GilL.M. MarquesJ. SalgadoD. Tongue Hyperpigmentation Associated with Temozolomide as a Single Agent: Case Report.Acta Med. Port.202235967267410.20344/amp.1598735263560
     [Google Scholar]
  276. FerreiraA.O. MarinhoR.T. VelosaJ. CostaJ.B. Geographic tongue and tenofovir.BMJ Case Rep.2013201310.1136/bcr‑2013‑00877423598934
     [Google Scholar]
  277. NarangodaK. WhitmoreJ. WorthW. NisarM. Case reports oral abstractso37. Persistent painful oral aphthous ulceration in patient streated with tocilizumab.Rheumatology (Oxford)201756Suppl. 203710.1093/rheumatology/kex061.037
     [Google Scholar]
  278. VenkateswaranN. KhianeyR. GenerosoA. Stevens Johnson Syndrome in a patient with giant cell arteritis during short term tocilizumab therapy.Cureus2020124e766210.7759/cureus.766232411563
     [Google Scholar]
  279. FriedmanD.I. Topirimate-induced burning mouth syndrome.Headache20105081383138510.1111/j.1526‑4610.2010.01720.x20561063
     [Google Scholar]
  280. GleesonP. TanakaT.I. AlawiF. AlhendiF. FadugbaO. Fixed drug eruption of the tongue due to trimethoprim-sulfamethoxazole.J Allergy Clin Immunol Pract.2020801328132910.1016/j.jaip.2019.08.019
     [Google Scholar]
  281. AlhowaryA. OdatH. AlaliO. Al-OmariA. Intraoperative angioedema induced by angiotensin II receptor blocker: A case report.Patient Saf. Surg.20181212710.1186/s13037‑018‑0174‑030250510
     [Google Scholar]
  282. KrispinskyA.J. RzepkaP.V. AwanF. KaffenbergerB.H. Geographic tongue induced by venetoclax in a patient with chronic lymphocytic leukemia.J. Clin. Aesthet. Dermatol.20191251131320968
     [Google Scholar]
/content/journals/cds/10.2174/0115748863299971240513061630
Loading
Drug-induced Tongue Disorders: A Comprehensive Literature Review
Curr Drug Saf 20, 148 (2025); https://doi.org/10.2174/0115748863299971240513061630
/content/journals/cds/10.2174/0115748863299971240513061630
/content/journals/cds/10.2174/0115748863299971240513061630
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Adverse drug reaction; black hairy tongue; burning tongue; gustatory dysfunction; tongue discoloration; tongue ulcer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test